Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Two Phase I Studies in Patients With Brain Metastases From Any Primary Histology, Followed by a Randomized Phase 2 Study of RO4929097 Combined With CNS Radiotherapy in Patients With Brain Metastases From Breast Cancer Whose Tumors Are Estrogen Receptor Negative

NCT01217411 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01217411
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01217411 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Two Phase I Studies in Patients With Brain Metastases From Any Primary Histology, Followed by a Randomized Phase 2 Study of RO4929097 Combined With CNS Radiotherapy in Patients With Brain Metastases From Breast Cancer Whose Tumors Are Estrogen Receptor Negative
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Terminated
Start date
October 1, 2010
Completion date
November 30, 2011
Enrollment
5 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

adult solid neoplasm, extensive stage lung small cell carcinoma, her2/neu negative, her2/neu positive, male breast carcinoma, metastatic malignant neoplasm in the brain, recurrent breast carcinoma, recurrent lung non-small cell carcinoma, recurrent lung small cell carcinoma, recurrent melanoma, stage iv breast cancer ajcc v6 and v7, stage iv cutaneous melanoma ajcc v6 and v7, stage iv lung non-small cell cancer ajcc v7